MediLink Therapeutics
China - SuzhouBiotechnology
Focus: MediLink Therapeutics is a China-based biotechnology company specializing in antibody-drug conjugates (ADCs) for oncology, currently in Series B stage with a pipeline focused on lung cancer and solid tumors.
Profile data last refreshed 20h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Total Funding
$70M
Open Jobs
0
About MediLink Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow MediLink Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Enhanced Body-Swap for Anorexia Nervosa
Eating DisordersClinical Trials (1)
NCT06799962AI and VR Devices for Eating Behavior Rehabilitation
N/AHelp build intelligence for MediLink Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.